News >

Brufsky Anticipates Significant Cost Reductions With Biosimilars

Brandon Scalea
Published: Thursday, Dec 20, 2018

Adam M. Brufsky, MD, PhD

Adam M. Brufsky, MD, PhD
For those who might question the equivalence of biosimilars to their reference products, it is important to remember the strict guidelines in place to ensure similarity before they reach the United States market, explained Adam M. Brufsky, MD, PhD.

, Brufsky shared insight on the impact of biosimilars in the field of oncology and outlined other strategies and steps that can be taken to mitigate cost when treating patients with breast cancer.

OncLive: How will the approved trastuzumab biosimilars impact the HER2-positive landscape?

Brufsky: While the trastuzumab biosimilars have been approved, they have not been marketed yet, which means that no one has actually started using them [in practice yet]. There are some biosimilars that will impact the field more quickly. For example, we have already been using the biosimilar G-CSF and there is now a pegylated biosimilar G-CSF that has been recently approved as well. Several trastuzumab biosimilars will probably receive approval in the next year or so.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Addressing Uncertainties in Oncology BiosimilarsApr 30, 20201.5
Publication Bottom Border
Border Publication